Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Time to Buy?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $16.78, but opened at $17.26. Daiichi Sankyo shares last traded at $16.9550, with a volume of 9,411 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DSNKY. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce”.

Daiichi Sankyo Trading Up 0.9%

The firm’s 50 day simple moving average is $16.71 and its two-hundred day simple moving average is $17.41. The stock has a market capitalization of $31.54 billion, a P/E ratio of 19.69, a P/E/G ratio of 3.31 and a beta of -0.18. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a return on equity of 14.22% and a net margin of 10.92%.Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.